How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comFirst-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
Description:
This is a Phase I, first-in-human study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).
Sponsor:
University of California, Davis
Phase:
Early Phase 1
Government Study Link:
NCT04665947 - Click here to see study onClinicalTrials.gov
Share your feedback
Help us improve your experience